Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Dec;116(8):3169–3174. doi: 10.1111/j.1476-5381.1995.tb15120.x

Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis.

K H Banner 1, N M Roberts 1, C P Page 1
PMCID: PMC1909182  PMID: 8719792

Abstract

1. The aims of this study were to compare the effects of selective inhibitors of the type 3, type 4 and type 5 phosphodiesterase (PDE) isoenzymes on the phytohaemagglutinin (PHA)-stimulated proliferation of human peripheral blood mononuclear cells (HPBM) from normals and subjects with atopic dermatitis (AD). 2. Mononuclear cells were isolated from peripheral venous blood of normals and subjects with AD. A concentration-response curve was carried out with PHA (0.5-5 micrograms ml-1) and a concentration which produced a submaximal stimulation of proliferation (2 micrograms ml-1) was selected for further experiments. HPBM (10(5) cells per well) were stimulated with PHA (2 micrograms ml-1) in the absence or presence of PDE inhibitor (0.01 microM-10 microM) and 24 h later [3H]-thymidine (0.1 microCi per well) was added. Cells were incubated for an additional 24 h period and [3H]-thymidine incorporation measured. 3. The type 4 PDE inhibitors (rolipram, RO 20-1724 and denbufylline) produced a concentration-related inhibition of proliferation of HPBM from normal and AD subjects. The IC50 for rolipram was significantly (P < 0.05) lower in HPBM from AD patients 0.28 microM (95% confidence limits (CL): 0.158-0.499, n = 5) vs normal subjects 2.6 microM (95% CL: 0.867-7.05, n = 5, P < 0.05) as were the IC50 values for denbufylline: 0.26 microM (95% CL: 0.152-0.440, n = 5) vs 1.84 microM (95% CL: 0.467-7.23, n = 5, P < 0.05) respectively and RO 20-1724: 1.49 microM (95% CL: 0.61 microM-3.64 microM) vs 6.46 microM (95% CL: 2.03 microM-20.46 microM), respectively. 4. The mixed type 3/4 inhibitors (zardaverine and benzafentrine) produced a concentration-related inhibition of proliferation of HPBM from normal and AD subjects. The IC50 value for zardaverine in HPBM from normal subjects: 1.8 microM (95% CL: 0.43 microM-7.85 microM, n = 4) was similar to that in AD subjects: 1.03 microM (95% CL: 0.48 microM-2.28 microM) as was the IC50 value for benzafentrine in normal 3.8 microM (95% CL: 2.45 microM-5.9 microM) and atopic 5.5 microM (95% CL: 3.84 microM-7.78 microM) HPBM. The type 5 PDE inhibitor, zaprinast was ineffective at inhibiting the proliferation of normal HPBM. The type 3 PDE inhibitor, siguazodan only inhibited [3H]-thymidine incorporation at a concentration of 10 microM. 5. These results show that combined inhibition of the type 3 and 4 PDE isoenzymes in HPBM from normal subjects has a greater antiproliferative effect than inhibition of the type 4 isoenzyme alone. In addition these data indicate that the proliferative response of HPBM from AD subjects is more sensitive to PDE 4 inhibition than the proliferation of HPBM from normals.

Full text

PDF
3169

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azzawi M., Johnston P. W., Majumdar S., Kay A. B., Jeffery P. K. T lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis. Am Rev Respir Dis. 1992 Jun;145(6):1477–1482. doi: 10.1164/ajrccm/145.6.1477. [DOI] [PubMed] [Google Scholar]
  2. Betz M., Fox B. S. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol. 1991 Jan 1;146(1):108–113. [PubMed] [Google Scholar]
  3. Butler J. M., Chan S. C., Stevens S., Hanifin J. M. Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis. J Allergy Clin Immunol. 1983 May;71(5):490–497. doi: 10.1016/0091-6749(83)90467-0. [DOI] [PubMed] [Google Scholar]
  4. Chan S. C., Hanifin J. M. Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes. J Lab Clin Med. 1993 Jan;121(1):44–51. [PubMed] [Google Scholar]
  5. Chan S. C., Reifsnyder D., Beavo J. A., Hanifin J. M. Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis. J Allergy Clin Immunol. 1993 Jun;91(6):1179–1188. doi: 10.1016/0091-6749(93)90321-6. [DOI] [PubMed] [Google Scholar]
  6. Cooper K. D., Kang K., Chan S. C., Hanifin J. M. Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro. J Invest Dermatol. 1985 Jun;84(6):477–482. doi: 10.1111/1523-1747.ep12272486. [DOI] [PubMed] [Google Scholar]
  7. Dent G., Giembycz M. A., Rabe K. F., Wolf B., Barnes P. J., Magnussen H. Theophylline suppresses human alveolar macrophage respiratory burst through phosphodiesterase inhibition. Am J Respir Cell Mol Biol. 1994 May;10(5):565–572. doi: 10.1165/ajrcmb.10.5.8179921. [DOI] [PubMed] [Google Scholar]
  8. Fink G., Mittelman M., Shohat B., Spitzer S. A. Theophylline-induced alterations in cellular immunity in asthmatic patients. Clin Allergy. 1987 Jul;17(4):313–316. doi: 10.1111/j.1365-2222.1987.tb02020.x. [DOI] [PubMed] [Google Scholar]
  9. Giembycz M. A. Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma? Biochem Pharmacol. 1992 May 28;43(10):2041–2051. doi: 10.1016/0006-2952(92)90160-k. [DOI] [PubMed] [Google Scholar]
  10. Giustina T. A., Chan S. C., Thiel M. L., Baker J. W., Hanifin J. M. Increased leukocyte sensitivity to phosphodiesterase inhibitors in atopic dermatitis: tachyphylaxis after theophylline therapy. J Allergy Clin Immunol. 1984 Sep;74(3 Pt 1):252–257. doi: 10.1016/0091-6749(84)90254-9. [DOI] [PubMed] [Google Scholar]
  11. Grewe S. R., Chan S. C., Hanifin J. M. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. J Allergy Clin Immunol. 1982 Dec;70(6):452–457. doi: 10.1016/0091-6749(82)90008-2. [DOI] [PubMed] [Google Scholar]
  12. Hadden J. W. Transmembrane signals in the activation of T lymphocytes by mitogenic antigens. Immunol Today. 1988 Jul-Aug;9(7-8):235–239. doi: 10.1016/0167-5699(88)91222-4. [DOI] [PubMed] [Google Scholar]
  13. Holden C. A., Chan S. C., Hanifin J. M. Monocyte localization of elevated cAMP phosphodiesterase activity in atopic dermatitis. J Invest Dermatol. 1986 Sep;87(3):372–376. doi: 10.1111/1523-1747.ep12524844. [DOI] [PubMed] [Google Scholar]
  14. Kammer G. M. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today. 1988 Jul-Aug;9(7-8):222–229. doi: 10.1016/0167-5699(88)91220-0. [DOI] [PubMed] [Google Scholar]
  15. Lahat N., Nir E., Horenstien L., Colin A. A. Effect of theophylline on the proportion and function of T-suppressor cells in asthmatic children. Allergy. 1985 Aug;40(6):453–457. doi: 10.1111/j.1398-9995.1985.tb02685.x. [DOI] [PubMed] [Google Scholar]
  16. Lichtenstein L. M., Henney C. S., Bourne H. R., Greenough W. B., 3rd Effects of cholera toxin on in vitro models of immediate and delayed hypersensitivity. Further evidence for the role of cyclic adenosine 3',5'-monophosphate. J Clin Invest. 1973 Mar;52(3):691–697. doi: 10.1172/JCI107230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lingk D. S., Chan M. A., Gelfand E. W. Increased cyclic adenosine monophosphate levels block progression but not initiation of human T cell proliferation. J Immunol. 1990 Jul 15;145(2):449–455. [PubMed] [Google Scholar]
  18. Mary D., Aussel C., Ferrua B., Fehlmann M. Regulation of interleukin 2 synthesis by cAMP in human T cells. J Immunol. 1987 Aug 15;139(4):1179–1184. [PubMed] [Google Scholar]
  19. Meskini N., Hosni M., Nemoz G., Lagarde M., Prigent A. F. Early increase in lymphocyte cyclic nucleotide phosphodiesterase activity upon mitogenic activation of human peripheral blood mononuclear cells. J Cell Physiol. 1992 Jan;150(1):140–148. doi: 10.1002/jcp.1041500119. [DOI] [PubMed] [Google Scholar]
  20. Milgrom H. Asthma--something old, something new .... Postgrad Med J. 1991;67 (Suppl 4):S13–S19. [PubMed] [Google Scholar]
  21. Novogrodsky A., Rubin A. L., Stenzel K. H. Selective suppression by adherent cells, prostaglandin, and cyclic AMP analogues of blastogenesis induced by different mitogens. J Immunol. 1979 Jan;122(1):1–7. [PubMed] [Google Scholar]
  22. Pazdur J., Krzystyniak K., Kopeć M. Effects of dipyridamole on human blood lymphocytes. Biochem Pharmacol. 1980 Sep 15;29(18):2515–2517. doi: 10.1016/0006-2952(80)90358-5. [DOI] [PubMed] [Google Scholar]
  23. Robicsek S. A., Blanchard D. K., Djeu J. Y., Krzanowski J. J., Szentivanyi A., Polson J. B. Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem Pharmacol. 1991 Jul 25;42(4):869–877. doi: 10.1016/0006-2952(91)90047-9. [DOI] [PubMed] [Google Scholar]
  24. Sawai T., Ikai K., Uehara M. Elevated cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from children with atopic dermatitis. Br J Dermatol. 1995 Jan;132(1):22–24. doi: 10.1111/j.1365-2133.1995.tb08619.x. [DOI] [PubMed] [Google Scholar]
  25. Shohat B., Volovitz B., Varsano I. Induction of suppressor T cells in asthmatic children by theophylline treatment. Clin Allergy. 1983 Sep;13(5):487–493. doi: 10.1111/j.1365-2222.1983.tb02626.x. [DOI] [PubMed] [Google Scholar]
  26. Smith K. A., Cantrell D. A. Interleukin 2 regulates its own receptors. Proc Natl Acad Sci U S A. 1985 Feb;82(3):864–868. doi: 10.1073/pnas.82.3.864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Souness J. E., Carter C. M., Diocee B. K., Hassall G. A., Wood L. J., Turner N. C. Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation. Biochem Pharmacol. 1991 Jul 25;42(4):937–945. doi: 10.1016/0006-2952(91)90056-b. [DOI] [PubMed] [Google Scholar]
  28. Takemoto D. J., Lee W. N., Kaplan S. A., Appleman M. M. Cyclic AMP phosphodiesterase in human lymphocytes and lymphoblasts. J Cyclic Nucleotide Res. 1978 Apr;4(2):123–132. [PubMed] [Google Scholar]
  29. Thompson W. J., Ross C. P., Pledger W. J., Strada S. J., Banner R. L., Hersh E. M. Cyclic adenosine 3':5'-monophosphate phosphodiesterase. Distinct forms in human lymphocytes and monocytes. J Biol Chem. 1976 Aug 25;251(16):4922–4929. [PubMed] [Google Scholar]
  30. Toribio M. L., Gutiérrez-Ramos J. C., Pezzi L., Marcos M. A., Martínez C. Interleukin-2-dependent autocrine proliferation in T-cell development. Nature. 1989 Nov 2;342(6245):82–85. doi: 10.1038/342082a0. [DOI] [PubMed] [Google Scholar]
  31. Torphy T. J., Undem B. J. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax. 1991 Jul;46(7):512–523. doi: 10.1136/thx.46.7.512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Ward A. J., McKenniff M., Evans J. M., Page C. P., Costello J. F. Theophylline--an immunomodulatory role in asthma? Am Rev Respir Dis. 1993 Mar;147(3):518–523. doi: 10.1164/ajrccm/147.3.518. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES